NCT03063320

Brief Summary

A 3-period randomized cross-over, controlled feeding study will be conducted to determine the effect of chronic spice consumption on postprandial vascular function. Participants will consume three test diets containing different amounts of spice. Each treatment period will last for 4 weeks. After each diet period a meal test will be conducted. Participants will consume a meal with a spice content corresponding to the diet period they have just completed. Endothelial function will be measured at 2 and 4 hours after meal consumption. Blood samples will also be taken during the 4 hours after meal consumption for measurement of lipids, immune and inflammatory markers.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
43

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jan 2017

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 25, 2017

Completed
27 days until next milestone

First Submitted

Initial submission to the registry

February 21, 2017

Completed
3 days until next milestone

First Posted

Study publicly available on registry

February 24, 2017

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 26, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 26, 2020

Completed
Last Updated

September 18, 2023

Status Verified

September 1, 2023

Enrollment Period

3.1 years

First QC Date

February 21, 2017

Last Update Submit

September 15, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in flow mediated dilation

    Endothelial function measured by FMD

    Change from baseline at 2 hours and 4 hours after meal consumption

Secondary Outcomes (6)

  • Lipid and lipoproteins

    Change from baseline during the 4 hours after meal consumption

  • Plasma Inflammatory cytokines

    Change from baseline during the 4 hours after meal consumption

  • Inflammatory cytokines in isolated peripheral blood mononuclear cells

    Change from baseline during the 4 hours after meal consumption

  • Glucose

    Change from baseline during the 4 hours after meal consumption

  • Insulin

    Change from baseline during the 4 hours after meal consumption

  • +1 more secondary outcomes

Study Arms (3)

Low Spice

ACTIVE COMPARATOR

The test meal (\~1200kcal and 44g fat) will contain \~0.6g of spice blend

Other: Spice blend

Moderate Spice

EXPERIMENTAL

The test meal (\~1200kcal and 44g fat) will contain \~3.7g of spice blend

Other: Spice blend

Culinary Spice

EXPERIMENTAL

The test meal (\~1200kcal and 44g fat) will contain \~7.4g of spice blend

Other: Spice blend

Interventions

Test spices include cardamom, coriander, cumin, ginger, paprika, red pepper, turmeric, cinnamon

Culinary SpiceLow SpiceModerate Spice

Eligibility Criteria

Age30 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Men and postmenopausal women Overweight or obese (25-35kg/m2) Non-smoking Waist circumference \>= 94cm for men and \>=80cm for women
  • At least one other of the following:
  • LDL- cholesterol \>130mg/dL
  • CRP \>1mg/L
  • Triglycerides \>=150mg/dL
  • HDL \<40mg/dL for men or \<50mg/dL for women
  • Systolic blood pressure \>= 130mmHg or diastolic \>= 85mmHg
  • Fasting glucose \>=100mg/dL

You may not qualify if:

  • Diabetes (fasting glucose \>126mg/dL)
  • Hypertension (systolic blood pressure \>160mmHg or diastolic blood pressure \>100mmHg)
  • Prescribed anti-hypertensive or glucose lowering drugs
  • Established cardiovascular disease, stroke, diabetes, liver, kidney or autoimmune disease
  • Use of cholesterol/lipid lowering medication or supplementation (psyllium, fish oil, soy lecithin, phytoestrogens) and botanicals
  • Pregnancy or lactation
  • Weight loss of \>=10% of body weight within the 6 months prior to enrolling in the study
  • Vegetarianism

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Penn State University

University Park, Pennsylvania, 16802, United States

Location

Study Officials

  • Penny M Kris-Etherton, PhD

    Penn State University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
Person assessing the outcome measures will be blinded to participant allocation
Purpose
PREVENTION
Intervention Model
CROSSOVER
Model Details: 3 period randomized cross over
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 21, 2017

First Posted

February 24, 2017

Study Start

January 25, 2017

Primary Completion

February 26, 2020

Study Completion

February 26, 2020

Last Updated

September 18, 2023

Record last verified: 2023-09

Data Sharing

IPD Sharing
Will not share

Locations